Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 1:20 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 5,126 matching trials from the live ClinicalTrials.gov search.
Filters: San Francisco, California Clear all
Completed Phase 1 Interventional

Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors

NCT01141244
View directory record Official record
Conditions
Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
temsirolimus, temozolomide, irinotecan hydrochloride, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 21 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
23
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2014 · Synced Nov 3, 2026, 1:20 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Effect of Obesity on Long-term Clinical Outcomes After Kidney Donation

NCT01368822
View directory record Official record
Conditions
Renal Dysfunction, Hypertension
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 9, 2012 · Synced Nov 3, 2026, 1:20 PM EST
Recruiting Not applicable Interventional

IMPRoving Outcomes in Vascular DisEase - Aortic Dissection

NCT06087029
View directory record Official record
Conditions
Type B Aortic Dissection
Interventions
TEVAR, Guideline directed medical therapy and surveillance of dissection
Procedure · Other
Lead sponsor
Duke University
Other
Eligibility
21 Years and older
Enrollment
1,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
64
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Nov 3, 2026, 1:20 PM EST
Active, not recruiting Not applicable Interventional

An Internet-based Program to Help Cancer Survivors Manage Pain

NCT04462302
View directory record Official record
Conditions
Cancer
Interventions
Internet-based pain coping skills program
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
149
States / cities
Fort Smith, Arkansas • Antioch, California • Dublin, California + 118 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Nov 3, 2026, 1:20 PM EST
Completed Phase 4 Interventional Results available

Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication

NCT01268553
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Treprostinil
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
3
States / cities
Tucson, Arizona • San Francisco, California • Torrance, California
Source: ClinicalTrials.gov public record
Updated Sep 1, 2017 · Synced Nov 3, 2026, 1:20 PM EST
Completed Phase 2 Interventional Results available

Staccato Prochlorperazine in Migraine (Out Patient)

NCT00422812
View directory record Official record
Conditions
Migraine Headache, Aura
Interventions
Inhaled Placebo, Inhaled PCZ 5 mg, Inhaled PCZ 7.5 mg, Inhaled PCZ 10 mg
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 70 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
25
States / cities
Scottsdale, Arizona • San Francisco, California • Santa Monica, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2018 · Synced Nov 3, 2026, 1:20 PM EST
Completed Phase 2 Interventional

Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer

NCT00003666
View directory record Official record
Conditions
Lung Cancer
Interventions
6-hydroxymethylacylfulvene
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years to 120 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2006
U.S. locations
48
States / cities
Birmingham, Alabama • La Jolla, California • San Francisco, California + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2016 · Synced Nov 3, 2026, 1:20 PM EST
Recruiting Phase 4 Interventional Accepts healthy volunteers

Ancillary Nocturnal Urinary Symptoms Analyses for TRIUMPH

NCT07829029
View directory record Official record
Conditions
Nocturia
Interventions
TolterodineTartrate ER, Mirabegron, Placebo
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
60 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Nov 3, 2026, 1:20 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Mindfulness-Based Stress Reduction in Dementia Caregivers

NCT04977245
View directory record Official record
Conditions
Mindfulness Based Stress Reduction, Caregiver Burnout, Caregiver Stress Syndrome, Dementia, Dementia Frontal, Frontotemporal Dementia, Frontotemporal Lobar Degeneration
Interventions
Mindfulness-Based Stress Reduction, Self-Guided Mindfulness eCourse
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Nov 3, 2026, 1:20 PM EST
Completed Not applicable Interventional

A Pilot Study of 566C80 for the Salvage Treatment of Toxoplasmic Encephalitis in Patients Infected With the Human Immunodeficiency Virus (HIV) Who Have Failed or Are Intolerant of Pyrimethamine-Sulfadiazine

NCT00001994
View directory record Official record
Conditions
Toxoplasmosis, Cerebral, HIV Infections
Interventions
Atovaquone
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
18
States / cities
Los Angeles, California • Oakland, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 1:20 PM EST
Completed No phase listed Observational Results available

Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project

NCT02948088
View directory record Official record
Conditions
Giant Cell Tumors
Interventions
Not listed
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Nov 3, 2026, 1:20 PM EST
Completed Phase 3 Interventional Results available

A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis

NCT01194570
View directory record Official record
Conditions
Multiple Sclerosis, Primary Progressive
Interventions
Ocrelizumab, Placebo
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 55 Years
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
37
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Phoenix, Arkansas + 31 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Nov 3, 2026, 1:20 PM EST
Completed Not applicable Interventional

A Cross-sectional Study of Lipoprotein(a) Levels in Patients With Documented History of Atherosclerotic Cardiovascular Disease (ASCVD)

NCT05378529
View directory record Official record
Conditions
Atherosclerotic Cardiovascular Disease
Interventions
Lp(a) Screening
Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 85 Years
Enrollment
39,480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
113
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2025 · Synced Nov 3, 2026, 1:20 PM EST
Not listed Phase 4 Interventional Results available

Descemet Endothelial Thickness Comparison Trial

NCT02373137
View directory record Official record
Conditions
Keratoplasty, Grafting, Corneal, Transplantation, Corneal, Transplantation, Cornea, Keratoplasty, Lamellar
Interventions
DSAEK, DMEK, Endoserter, Prednisolone, Ofloxacin, Tropicamide, Phenylephrine, Jones Tube
Procedure · Device · Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
3
States / cities
Palo Alto, California • San Francisco, California • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Nov 3, 2026, 1:20 PM EST
Terminated Phase 1 Interventional

A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

NCT06254495
View directory record Official record
Conditions
Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic
Interventions
PF-08046044/SGN-35C
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
27
States / cities
Duarte, California • San Francisco, California • Coral Gables, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 3, 2026, 1:20 PM EST
Withdrawn Phase 4 Interventional

Automated Ventilator Controlled Weaning vs Daily Spontaneous Breathing Trial in Difficult to Wean ICU Patients

NCT00813839
View directory record Official record
Conditions
Mechanical Ventilation, Weaning
Interventions
daily weaning trails
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 8, 2015 · Synced Nov 3, 2026, 1:20 PM EST
Completed Not applicable Interventional Results available

Photobiomodulation for Improving Brain Function in Dementia (PBM Dementia)

NCT03160027
View directory record Official record
Conditions
Dementia, Alzheimer Type
Interventions
Vielight Neuro Gamma
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
50 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2020 · Synced Nov 3, 2026, 1:20 PM EST
Terminated Not applicable Interventional

Comparison of Barium Enema, Computed Tomographic Colonography, and Colonoscopy in Detecting Colon Cancer

NCT00016029
View directory record Official record
Conditions
Colorectal Cancer
Interventions
screening questionnaire administration, barium enema injection, computed tomography, computed tomography colonography, diagnostic colonoscopy, screening colonoscopy
Other · Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
775 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
14
States / cities
La Jolla, California • San Francisco, California • Vero Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2013 · Synced Nov 3, 2026, 1:20 PM EST
Active, not recruiting Phase 3 Interventional

A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

NCT05500222
View directory record Official record
Conditions
NASH, Cirrhosis, Liver
Interventions
Resmetirom, Placebo
Drug
Lead sponsor
Madrigal Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
845 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
96
States / cities
Birmingham, Alabama • Chandler, Arizona • Peoria, Arizona + 76 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 3, 2026, 1:20 PM EST
Completed Phase 3 Interventional Results available

Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis

NCT03439254
View directory record Official record
Conditions
Compensated Cirrhosis, Nonalcoholic Steatohepatitis
Interventions
Obeticholic acid (10 mg), Obeticholic acid (10 mg to 25 mg), Placebo
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
919 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
120
States / cities
Dothan, Alabama • Madison, Alabama • Chandler, Arizona + 96 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2023 · Synced Nov 3, 2026, 1:20 PM EST
Recruiting Phase 2 Interventional

A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

NCT07149857
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Cilta-cel, Cyclophosphamide, Induction therapy, Fludarabine
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
7
States / cities
San Francisco, California • Tampa, Florida • Iowa City, Iowa + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 3, 2026, 1:20 PM EST
Completed Phase 1Phase 2 Interventional

Biochemotherapy and Bevacizumab Followed by Consolidation Therapy With Ipilimumab for Metastatic Melanoma

NCT01743157
View directory record Official record
Conditions
Metastatic Melanoma
Interventions
Biochemo + bevacizumab then ipilimumab
Drug
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 29, 2013 · Synced Nov 3, 2026, 1:20 PM EST
Completed Phase 3 Interventional Results available

Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma

NCT03710876
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
rAd-IFN, Celecoxib Oral Product, Gemcitabine
Biological · Drug
Lead sponsor
Ferring Ventures Limited
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Nov 3, 2026, 1:20 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

De-implementation of Outdated Colonoscopy Surveillance Interval Recommendations Among Patients With Low-risk Adenomas

NCT05389397
View directory record Official record
Conditions
Polyp of Colon
Interventions
Outreach
Behavioral
Lead sponsor
Kaiser Permanente
Other
Eligibility
54 Years to 70 Years
Enrollment
604 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Nov 3, 2026, 1:20 PM EST